The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Abbvie; Advaxis; Celgene
Research Funding - Cascadian Therapeutics (Inst); Celgene (Inst); Celldex (Inst); Genentech (Inst); Juno Therapeutics (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst)
 
Research Funding - Juno Therapeutics (Inst)
Phase I study of immunotherapy for advanced ROR1+ malignancies with autologous ROR1-specific chimeric antigen receptor-modified (CAR)-T cells.
 
Jennifer M Specht
No Relationships to Disclose
 
Sylvia Lee
No Relationships to Disclose
 
Cameron Turtle
Research Funding - Juno Therapeutics (Inst)
 
Carolina Berger
No Relationships to Disclose
 
Josh Veatch
No Relationships to Disclose
 
Ted Gooley
No Relationships to Disclose
 
Erin Mullane
No Relationships to Disclose
 
Colette Chaney
No Relationships to Disclose
 
Stanley Riddell
Stock and Other Ownership Interests - Juno Therapeutics
Consulting or Advisory Role - Juno Therapeutics
Research Funding - Juno Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Juno Therapeutics
 
David G. Maloney
Research Funding - Juno Therapeutics (Inst); Kite, a Gilead company (Inst)